All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-05-26.
From the record
Krystal Biotech, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2022-05-26) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
5 filed years; profitable in 3 of 5.
From the record
Krystal Biotech, Inc.'s 5 filed years say what it did: it rose in 2 of 2 years; it never fell from a peak; net income was positive in 3 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 5.5% a year. 0% of cash flow returned. Insiders: 142 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Krystal Biotech, Inc.'s diluted share count grew about 5.5% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 142 sales (132 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 17%: 17¢ of profit per shareholder dollar. Leverage 9%: owes 9¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Krystal Biotech, Inc. earned about 17 cents of profit for every dollar of shareholders' money. Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count grew 0.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 9% of 102 in its family; net margin 52.6%.
From the record
Krystal Biotech, Inc.'s standing among 102 graded names in its industry family: revenue of $389 million in fiscal 2025 ranks in the top 16% by size; a net margin of 52.6% ranks in the top 2% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 13% of 110 in its family for leadership; chief executive since 2017.
From the record
Krystal Biotech, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Krishnan, Krish S (President and CEO, as filed), filing under that title since 2017-09-19, 9.1 years (top 11% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.7 years (top 24%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 5%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 44% of 92 in its family for room to expand.
From the record
Krystal Biotech, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $496 million against no long-term debt tagged leaves 37.2% of its assets as net cash, top 42% of its family; cash from operations less capital spending is 48.5% of revenue (top 1%); research spending of 14.9% of revenue (bottom 10%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 42% of 100 in its family for growth drivers.
From the record
Krystal Biotech, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 34% (top 39%); research spending grew 11% a year (top 31%); capital spending grew -39.1% a year (bottom 44%) (its annual reports). Krystal Biotech, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 26% of 72 in its family for expectations against reality.
From the record
Krystal Biotech, Inc.'s newest year against its own record: net income of $205 million against a prior three-year average of $13 million (top 1%); a net margin of 52.6% against 26.1% before (bottom 49%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made